Boehringer widens fibrosis drug’s approval path after boosting lung function in 2nd phase 3 trial

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it will seek FDA approval for.